top of page

Life Saving Stem Cell Therapy Platform

Using Wharton-Jelly Mesenchymal Stem Cells for Immune Disorders and Tissue Repair
 

1 DRUG 3 ACTIONS

StemInov is developing WhartSep, a large scale and off-the-shelf treatment.

WhartSep is the first drug candidate having  3 complementary actions to tackle the complex physiopathology of severe pneumonia

1

Anti Bacterial Effects

Direct and indirect antibacterial by effect on phagocytic cells capable of eliminating the pathogenic microorganisms responsible for the infection

2

Immunomodulation

Unique Modulation of inflammation: WhartSep acquires a pro- or anti-inflammatory phenotype depending on environment

3

Organ protection

Ability to migrate to damaged organs and tropism for lungs

Unique advantages for a strong unmet medical need

THERAPEUTIC EFFECTIVENESS AND TOLERANCE OF FETAL SOURCE

NON LIMITED & NON INVASIVE SOURCING

SCALABLE & READY TO USE OFF THE SHELF PRODUCT

OUR TEAM

Ecole Centrale Lyon
Master EM Lyon

HEC Challenge + 2020-2

5y experience in Eurofins Genomics

JH.png
JH.png

Julie HUTIN 

CEO & Co-founder

PU-PH - Head of Cellular Therapy Unit and Tissue Banking, Cord Blood Banking (UTCT)

Head of a CNRS Team

Lead to the patent operated by StemInov

70 Publications in ATMP over the last 12 yrs

DB.png

Danièle BENSOUSSAN 

CSO & Co-founder

DB.png

Eric is a serial entrepreneur who combines strong strategic, technological and managerial experience with proven track record of deal-making and fund-raising.  He is the CEO of PDC line Pharma

EH.png

Eric HALIOUA

Strategy

EH.png

Prof. in an Intensive Care Unit of a University Hospital. In charge of  designing and conducting experimental and translational research towards sepsis

PE.png

PE CHARLES

Clinical Strategy

PE.png

Industrial Pharmacist

Cell Production GMP Unit Expert

CMC expert in cell and gene therapy

Several GMP accreditations

CD.png

Claude DEDRY

CMC

CD.png
bottom of page